EMA publishes ICH Reflection Paper on RWD / RWE
Recommendation
Tuesday, 29 October 2024 9 .00 - 17.00 h
GMP / GVP Interfaces and Challenges
The European Medicines Agency (EMA) has published the final version of the ICH Reflection Paper on the harmonization of the possible use of Real-World Data (RWD) and Real-World Evidence (RWE) in the regulatory environment.
The draft ICH Reflection Paper on RWE was published for public consultation last year. The paper was revised further to comments received during the public consultation held from June to September 2023. In addition, a summary report of comments received on the Reflection Paper during public consultation has been published on the ICH Reflection Papers website.
The reflection paper aims to harmonize RWE terminology. It also looks to enable the convergence of general principles for planning and reporting studies using RWD to support regulatory decision-making.
The document identifies the following areas for harmonization:
- Convergence on terminology for real-world data and real-world evidence
- Format for protocols and reports of study results submitted to regulatory agencies throughout the lifecycle of medicines
- Promoting registration of protocols and reports
In addition, the paper includes a useful Annex summarizing existing regulatory guidances and other resources related to RWD / RWE.
More information is available in the ICH reflection paper on pursuing opportunities for harmonisation in using real-world data to generate RWE, with a focus on effectiveness of medicines published on the EMA website.
Related GMP News
01.10.2024EMA publishes Comments on ICH E2D
01.10.2024GVP Updates
03.09.2024Real-World Data: FDA's final Guidance on the Use of eHRs in Clinical Studies
03.09.2024New USP Chapter for Food Supplements
20.06.2024EMA's Reflection Paper on the Use of Real-World Data in Non-Interventional Studies